Norsk
Norwegian Society of Hematology

Perform a systematic frailty assessment before initiating treatment and when reassessing treatment in patients above 70-75 years

9. JUNI 2026

Rationale:

Frailty is an important predictor of survival and risk of complications and should help guide both the choice of treatment and its intensity.

References: 

  • Scheepers ERM, Vondeling AM, Thielen N, mfl. Geriatric assessment in older patients with a hematologic malignancy: A systematic review. Haematologica. 2020
  • Palumbo A, Bringhen S, Mateos MV, mfl. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An IMWG report. Blood. 2015